ArticleOncotarget2017
The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer's syndrome.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies.Frontiers in nutrition · 2021Pooled it
- Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes.Medical oncology (Northwood, London, England) · 2020Pooled it
- Ketone bodies in kidney diseases: novel insights.Frontiers in immunology · 2026Review
- Dietary protection against the visual and motor deficits induced by experimental autoimmune encephalomyelitis.Frontiers in neurology · 2023Article
- The Effect of Ketogenic Diet on Shared Risk Factors of Cardiovascular Disease and Cancer.Nutrients · 2022Review
- Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes.EMBO molecular medicine · 2021Article
- Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities.Current issues in molecular biology · 2021Review
- Ketogenic Diets and their Therapeutic Potential on Breast Cancer: A Systemic Review.Cancer management and research · 2021Review
- A gut butyrate-producing bacteriumOncology letters · 2020Article
- Ketogenic diet in the treatment of cancer - Where do we stand?Molecular metabolism · 2020Review
- Untargeted Metabolomics Reveals Molecular Effects of Ketogenic Diet on Healthy and Tumor Xenograft Mouse Models.International journal of molecular sciences · 2019Article
- Ketogenic diet in cancer therapy.Aging · 2018Article
- Article
- The Role of Ketogenic Diet in the Treatment of Neuroblastoma.Integrative cancer therapiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ketogenic diet (KD), a high-fat low-carbohydrate diet, has shown some efficacy in the treatment of certain types of tumors such as brain tumors and neuroblastoma. These tumors are characterized by the Warburg effect. Because renal cell carcinoma (RCC) presents similar energetic features as neuroblastoma, KD might also be effective in the treatment of RCC. To test this, we established xenografts with RCC 786-O cells in CD-1 nu/nu mice and then randomized them to a control diet or to KDs with different triglyceride contents. Although the KDs tended to reduce tumor growth, mouse survival was dramatically reduced due to massive weight loss. A possible explanation comes from observations of human RCC patients, who often experience secondary non-metastatic hepatic dysfunction due to secretion of high levels of inflammatory cytokines by the RCCs. Measurement of the mRNA levels of tumor necrosis factor alpha (TNFα) and interleukin-6 revealed high expression in the RCC xenografts compared to the original 786-O cells. The expression of TNFα, interleukin-6 and C-reactive protein were all increased in the livers of tumor-bearing mice, and KD significantly boosted their expression. KDs did not cause weight loss or liver inflammation in healthy mice, suggesting that KDs are per se safe, but might be contraindicated in the treatment of RCC patients presenting with Stauffer's syndrome, because they potentially worsen the associated hepatic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.